nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—ABCB1—peripheral nervous system neoplasm	0.226	1	CbGaD
Cyclophosphamide—CYP2C18—Tretinoin—peripheral nervous system neoplasm	0.101	0.195	CbGbCtD
Cyclophosphamide—CYP2A6—Tretinoin—peripheral nervous system neoplasm	0.049	0.0947	CbGbCtD
Cyclophosphamide—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0335	0.0647	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0335	0.0647	CbGbCtD
Cyclophosphamide—CYP2B6—Tretinoin—peripheral nervous system neoplasm	0.0319	0.0616	CbGbCtD
Cyclophosphamide—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0252	0.0485	CbGbCtD
Cyclophosphamide—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0242	0.0467	CbGbCtD
Cyclophosphamide—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0176	0.034	CbGbCtD
Cyclophosphamide—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0176	0.034	CbGbCtD
Cyclophosphamide—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0169	0.0326	CbGbCtD
Cyclophosphamide—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.0154	0.0297	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.0154	0.0297	CbGbCtD
Cyclophosphamide—CYP2B6—Cisplatin—peripheral nervous system neoplasm	0.0137	0.0264	CbGbCtD
Cyclophosphamide—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0122	0.0236	CbGbCtD
Cyclophosphamide—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0115	0.0223	CbGbCtD
Cyclophosphamide—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0106	0.0204	CbGbCtD
Cyclophosphamide—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0105	0.0204	CbGbCtD
Cyclophosphamide—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0102	0.0196	CbGbCtD
Cyclophosphamide—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00981	0.0189	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—peripheral nervous system neoplasm	0.00916	0.0177	CbGbCtD
Cyclophosphamide—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00752	0.0145	CbGbCtD
Cyclophosphamide—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00722	0.0139	CbGbCtD
Cyclophosphamide—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00701	0.0135	CbGbCtD
Cyclophosphamide—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00689	0.0133	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0047	0.00907	CbGbCtD
Cyclophosphamide—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0045	0.00869	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00443	0.00854	CbGbCtD
Cyclophosphamide—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00413	0.00796	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00281	0.00543	CbGbCtD
Cyclophosphamide—Cough—Etoposide—peripheral nervous system neoplasm	5.18e-05	0.000202	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	5.18e-05	0.000202	CcSEcCtD
Cyclophosphamide—Headache—Topotecan—peripheral nervous system neoplasm	5.17e-05	0.000202	CcSEcCtD
Cyclophosphamide—Rash—Isotretinoin—peripheral nervous system neoplasm	5.17e-05	0.000202	CcSEcCtD
Cyclophosphamide—Rash—Tretinoin—peripheral nervous system neoplasm	5.17e-05	0.000202	CcSEcCtD
Cyclophosphamide—Tachycardia—Cisplatin—peripheral nervous system neoplasm	5.16e-05	0.000202	CcSEcCtD
Cyclophosphamide—Dermatitis—Tretinoin—peripheral nervous system neoplasm	5.16e-05	0.000201	CcSEcCtD
Cyclophosphamide—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	5.16e-05	0.000201	CcSEcCtD
Cyclophosphamide—Fatigue—Vincristine—peripheral nervous system neoplasm	5.16e-05	0.000201	CcSEcCtD
Cyclophosphamide—Convulsion—Etoposide—peripheral nervous system neoplasm	5.15e-05	0.000201	CcSEcCtD
Cyclophosphamide—Vomiting—Melphalan—peripheral nervous system neoplasm	5.14e-05	0.000201	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	5.14e-05	0.0002	CcSEcCtD
Cyclophosphamide—Headache—Isotretinoin—peripheral nervous system neoplasm	5.13e-05	0.0002	CcSEcCtD
Cyclophosphamide—Headache—Tretinoin—peripheral nervous system neoplasm	5.13e-05	0.0002	CcSEcCtD
Cyclophosphamide—Hypertension—Etoposide—peripheral nervous system neoplasm	5.13e-05	0.0002	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	5.12e-05	0.0002	CcSEcCtD
Cyclophosphamide—Pain—Vincristine—peripheral nervous system neoplasm	5.12e-05	0.0002	CcSEcCtD
Cyclophosphamide—Constipation—Vincristine—peripheral nervous system neoplasm	5.12e-05	0.0002	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	5.11e-05	0.0002	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	5.11e-05	0.0002	CcSEcCtD
Cyclophosphamide—Rash—Melphalan—peripheral nervous system neoplasm	5.1e-05	0.000199	CcSEcCtD
Cyclophosphamide—Dermatitis—Melphalan—peripheral nervous system neoplasm	5.09e-05	0.000199	CcSEcCtD
Cyclophosphamide—Chest pain—Etoposide—peripheral nervous system neoplasm	5.06e-05	0.000197	CcSEcCtD
Cyclophosphamide—Anorexia—Cisplatin—peripheral nervous system neoplasm	5.04e-05	0.000197	CcSEcCtD
Cyclophosphamide—Discomfort—Etoposide—peripheral nervous system neoplasm	5e-05	0.000195	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	4.98e-05	0.000194	CcSEcCtD
Cyclophosphamide—Hypotension—Cisplatin—peripheral nervous system neoplasm	4.94e-05	0.000193	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	4.94e-05	0.000193	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	4.93e-05	0.000193	CcSEcCtD
Cyclophosphamide—Urticaria—Alitretinoin—peripheral nervous system neoplasm	4.93e-05	0.000193	CcSEcCtD
Cyclophosphamide—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	4.91e-05	0.000192	CcSEcCtD
Cyclophosphamide—Nausea—Topotecan—peripheral nervous system neoplasm	4.91e-05	0.000191	CcSEcCtD
Cyclophosphamide—Confusional state—Etoposide—peripheral nervous system neoplasm	4.89e-05	0.000191	CcSEcCtD
Cyclophosphamide—Nausea—Tretinoin—peripheral nervous system neoplasm	4.87e-05	0.00019	CcSEcCtD
Cyclophosphamide—Nausea—Isotretinoin—peripheral nervous system neoplasm	4.87e-05	0.00019	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—peripheral nervous system neoplasm	4.86e-05	0.00019	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	4.85e-05	0.000189	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	4.82e-05	0.000188	CcSEcCtD
Cyclophosphamide—Infection—Etoposide—peripheral nervous system neoplasm	4.82e-05	0.000188	CcSEcCtD
Cyclophosphamide—Asthenia—Dactinomycin—peripheral nervous system neoplasm	4.8e-05	0.000188	CcSEcCtD
Cyclophosphamide—Nausea—Melphalan—peripheral nervous system neoplasm	4.8e-05	0.000188	CcSEcCtD
Cyclophosphamide—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	4.75e-05	0.000185	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	4.75e-05	0.000185	CcSEcCtD
Cyclophosphamide—Tachycardia—Etoposide—peripheral nervous system neoplasm	4.73e-05	0.000185	CcSEcCtD
Cyclophosphamide—Body temperature increased—Vincristine—peripheral nervous system neoplasm	4.73e-05	0.000185	CcSEcCtD
Cyclophosphamide—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	4.72e-05	0.000184	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	4.69e-05	0.000183	CcSEcCtD
Cyclophosphamide—Anorexia—Etoposide—peripheral nervous system neoplasm	4.62e-05	0.00018	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	4.61e-05	0.00018	CcSEcCtD
Cyclophosphamide—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	4.6e-05	0.00018	CcSEcCtD
Cyclophosphamide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	4.58e-05	0.000179	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	4.57e-05	0.000179	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	4.57e-05	0.000179	CcSEcCtD
Cyclophosphamide—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	4.54e-05	0.000177	CcSEcCtD
Cyclophosphamide—Hypotension—Etoposide—peripheral nervous system neoplasm	4.53e-05	0.000177	CcSEcCtD
Cyclophosphamide—Pain—Cisplatin—peripheral nervous system neoplasm	4.52e-05	0.000177	CcSEcCtD
Cyclophosphamide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	4.45e-05	0.000174	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	4.41e-05	0.000172	CcSEcCtD
Cyclophosphamide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	4.39e-05	0.000171	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	4.36e-05	0.00017	CcSEcCtD
Cyclophosphamide—Paraesthesia—Etoposide—peripheral nervous system neoplasm	4.35e-05	0.00017	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—peripheral nervous system neoplasm	4.35e-05	0.00017	CcSEcCtD
Cyclophosphamide—Dyspnoea—Etoposide—peripheral nervous system neoplasm	4.32e-05	0.000169	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.000168	CcSEcCtD
Cyclophosphamide—Asthenia—Vincristine—peripheral nervous system neoplasm	4.29e-05	0.000168	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—peripheral nervous system neoplasm	4.28e-05	0.000167	CcSEcCtD
Cyclophosphamide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	4.26e-05	0.000166	CcSEcCtD
Cyclophosphamide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	4.25e-05	0.000166	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000165	CcSEcCtD
Cyclophosphamide—Rash—Dactinomycin—peripheral nervous system neoplasm	4.22e-05	0.000165	CcSEcCtD
Cyclophosphamide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	4.21e-05	0.000164	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000164	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—peripheral nervous system neoplasm	4.19e-05	0.000163	CcSEcCtD
Cyclophosphamide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	4.18e-05	0.000163	CcSEcCtD
Cyclophosphamide—Fatigue—Etoposide—peripheral nervous system neoplasm	4.18e-05	0.000163	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	4.18e-05	0.000163	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.000162	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.000162	CcSEcCtD
Cyclophosphamide—Pain—Etoposide—peripheral nervous system neoplasm	4.14e-05	0.000162	CcSEcCtD
Cyclophosphamide—Constipation—Etoposide—peripheral nervous system neoplasm	4.14e-05	0.000162	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	4.14e-05	0.000162	CcSEcCtD
Cyclophosphamide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	4.11e-05	0.00016	CcSEcCtD
Cyclophosphamide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	4.09e-05	0.00016	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—peripheral nervous system neoplasm	4.08e-05	0.000159	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—peripheral nervous system neoplasm	4.06e-05	0.000159	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—peripheral nervous system neoplasm	4.02e-05	0.000157	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	3.99e-05	0.000156	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000156	CcSEcCtD
Cyclophosphamide—Nausea—Dactinomycin—peripheral nervous system neoplasm	3.98e-05	0.000155	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	3.98e-05	0.000155	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000155	CcSEcCtD
Cyclophosphamide—Dizziness—Vincristine—peripheral nervous system neoplasm	3.96e-05	0.000154	CcSEcCtD
Cyclophosphamide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	3.95e-05	0.000154	CcSEcCtD
Cyclophosphamide—Rash—Alitretinoin—peripheral nervous system neoplasm	3.92e-05	0.000153	CcSEcCtD
Cyclophosphamide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	3.91e-05	0.000153	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.000153	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	3.9e-05	0.000152	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.000152	CcSEcCtD
Cyclophosphamide—Headache—Alitretinoin—peripheral nervous system neoplasm	3.89e-05	0.000152	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000151	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	3.86e-05	0.000151	CcSEcCtD
Cyclophosphamide—Urticaria—Etoposide—peripheral nervous system neoplasm	3.85e-05	0.00015	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	3.84e-05	0.00015	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.00015	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.00015	CcSEcCtD
Cyclophosphamide—Rhinitis—Epirubicin—peripheral nervous system neoplasm	3.83e-05	0.00015	CcSEcCtD
Cyclophosphamide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	3.83e-05	0.00015	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	3.83e-05	0.00015	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.000149	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.000149	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	3.8e-05	0.000149	CcSEcCtD
Cyclophosphamide—Vomiting—Vincristine—peripheral nervous system neoplasm	3.8e-05	0.000148	CcSEcCtD
Cyclophosphamide—Asthenia—Cisplatin—peripheral nervous system neoplasm	3.8e-05	0.000148	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000147	CcSEcCtD
Cyclophosphamide—Rash—Vincristine—peripheral nervous system neoplasm	3.77e-05	0.000147	CcSEcCtD
Cyclophosphamide—Dermatitis—Vincristine—peripheral nervous system neoplasm	3.77e-05	0.000147	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000147	CcSEcCtD
Cyclophosphamide—Headache—Vincristine—peripheral nervous system neoplasm	3.75e-05	0.000146	CcSEcCtD
Cyclophosphamide—Nausea—Alitretinoin—peripheral nervous system neoplasm	3.69e-05	0.000144	CcSEcCtD
Cyclophosphamide—Visual impairment—Epirubicin—peripheral nervous system neoplasm	3.69e-05	0.000144	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	3.68e-05	0.000144	CcSEcCtD
Cyclophosphamide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	3.62e-05	0.000141	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	3.62e-05	0.000141	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000141	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	3.57e-05	0.000139	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—peripheral nervous system neoplasm	3.57e-05	0.000139	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	3.56e-05	0.000139	CcSEcCtD
Cyclophosphamide—Nausea—Vincristine—peripheral nervous system neoplasm	3.55e-05	0.000139	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—peripheral nervous system neoplasm	3.55e-05	0.000139	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	3.55e-05	0.000138	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	3.54e-05	0.000138	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	3.54e-05	0.000138	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	3.52e-05	0.000137	CcSEcCtD
Cyclophosphamide—Asthenia—Etoposide—peripheral nervous system neoplasm	3.48e-05	0.000136	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—peripheral nervous system neoplasm	3.43e-05	0.000134	CcSEcCtD
Cyclophosphamide—Pruritus—Etoposide—peripheral nervous system neoplasm	3.43e-05	0.000134	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	3.42e-05	0.000133	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	3.41e-05	0.000133	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—peripheral nervous system neoplasm	3.38e-05	0.000132	CcSEcCtD
Cyclophosphamide—Vomiting—Cisplatin—peripheral nervous system neoplasm	3.36e-05	0.000131	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	3.35e-05	0.000131	CcSEcCtD
Cyclophosphamide—Rash—Cisplatin—peripheral nervous system neoplasm	3.34e-05	0.00013	CcSEcCtD
Cyclophosphamide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	3.33e-05	0.00013	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—peripheral nervous system neoplasm	3.33e-05	0.00013	CcSEcCtD
Cyclophosphamide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	3.32e-05	0.000129	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	3.3e-05	0.000129	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—peripheral nervous system neoplasm	3.28e-05	0.000128	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	3.26e-05	0.000127	CcSEcCtD
Cyclophosphamide—Dizziness—Etoposide—peripheral nervous system neoplasm	3.21e-05	0.000125	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	3.2e-05	0.000125	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—peripheral nervous system neoplasm	3.17e-05	0.000124	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000123	CcSEcCtD
Cyclophosphamide—Nausea—Cisplatin—peripheral nervous system neoplasm	3.14e-05	0.000123	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—peripheral nervous system neoplasm	3.14e-05	0.000122	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—peripheral nervous system neoplasm	3.13e-05	0.000122	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	3.09e-05	0.000121	CcSEcCtD
Cyclophosphamide—Vomiting—Etoposide—peripheral nervous system neoplasm	3.08e-05	0.00012	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—peripheral nervous system neoplasm	3.08e-05	0.00012	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—peripheral nervous system neoplasm	3.08e-05	0.00012	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—peripheral nervous system neoplasm	3.06e-05	0.000119	CcSEcCtD
Cyclophosphamide—Rash—Etoposide—peripheral nervous system neoplasm	3.06e-05	0.000119	CcSEcCtD
Cyclophosphamide—Dermatitis—Etoposide—peripheral nervous system neoplasm	3.05e-05	0.000119	CcSEcCtD
Cyclophosphamide—Headache—Etoposide—peripheral nervous system neoplasm	3.04e-05	0.000119	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	3.02e-05	0.000118	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—peripheral nervous system neoplasm	3e-05	0.000117	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—peripheral nervous system neoplasm	2.98e-05	0.000116	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	0.000116	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—peripheral nervous system neoplasm	2.94e-05	0.000115	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—peripheral nervous system neoplasm	2.9e-05	0.000113	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	2.9e-05	0.000113	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—peripheral nervous system neoplasm	2.88e-05	0.000113	CcSEcCtD
Cyclophosphamide—Nausea—Etoposide—peripheral nervous system neoplasm	2.88e-05	0.000112	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—peripheral nervous system neoplasm	2.87e-05	0.000112	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	2.86e-05	0.000112	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—peripheral nervous system neoplasm	2.85e-05	0.000111	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—peripheral nervous system neoplasm	2.83e-05	0.000111	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—peripheral nervous system neoplasm	2.83e-05	0.000111	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	2.83e-05	0.000111	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—peripheral nervous system neoplasm	2.83e-05	0.00011	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—peripheral nervous system neoplasm	2.8e-05	0.000109	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—peripheral nervous system neoplasm	2.78e-05	0.000108	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	2.76e-05	0.000108	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—peripheral nervous system neoplasm	2.74e-05	0.000107	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—peripheral nervous system neoplasm	2.72e-05	0.000106	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	2.72e-05	0.000106	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—peripheral nervous system neoplasm	2.72e-05	0.000106	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—peripheral nervous system neoplasm	2.7e-05	0.000105	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—peripheral nervous system neoplasm	2.69e-05	0.000105	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—peripheral nervous system neoplasm	2.67e-05	0.000104	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—peripheral nervous system neoplasm	2.67e-05	0.000104	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	2.66e-05	0.000104	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	2.66e-05	0.000104	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—peripheral nervous system neoplasm	2.65e-05	0.000104	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	2.63e-05	0.000103	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	0.000102	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	0.000102	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	0.000102	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	2.59e-05	0.000101	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—peripheral nervous system neoplasm	2.59e-05	0.000101	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—peripheral nervous system neoplasm	2.54e-05	9.91e-05	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	2.53e-05	9.89e-05	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	2.51e-05	9.81e-05	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.51e-05	9.81e-05	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—peripheral nervous system neoplasm	2.5e-05	9.75e-05	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	2.48e-05	9.66e-05	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—peripheral nervous system neoplasm	2.47e-05	9.65e-05	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	2.46e-05	9.61e-05	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	2.45e-05	9.58e-05	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.44e-05	9.52e-05	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	2.43e-05	9.49e-05	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.42e-05	9.45e-05	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.4e-05	9.35e-05	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	2.36e-05	9.22e-05	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	2.35e-05	9.17e-05	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—peripheral nervous system neoplasm	2.34e-05	9.14e-05	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—peripheral nervous system neoplasm	2.32e-05	9.07e-05	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—peripheral nervous system neoplasm	2.32e-05	9.07e-05	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	2.29e-05	8.94e-05	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	2.26e-05	8.81e-05	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.24e-05	8.75e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.24e-05	8.74e-05	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.19e-05	8.53e-05	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.17e-05	8.46e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.16e-05	8.42e-05	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	8.39e-05	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	8.39e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.15e-05	8.38e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.07e-05	8.09e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2e-05	7.81e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2e-05	7.8e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	1.99e-05	7.76e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—peripheral nervous system neoplasm	1.95e-05	7.61e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—peripheral nervous system neoplasm	1.92e-05	7.5e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	1.86e-05	7.26e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	1.85e-05	7.23e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	1.8e-05	7.04e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—peripheral nervous system neoplasm	1.8e-05	7.01e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	1.78e-05	6.94e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.73e-05	6.74e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.72e-05	6.71e-05	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—peripheral nervous system neoplasm	1.71e-05	6.69e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.71e-05	6.68e-05	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—peripheral nervous system neoplasm	1.7e-05	6.64e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.66e-05	6.49e-05	CcSEcCtD
Cyclophosphamide—Nausea—Epirubicin—peripheral nervous system neoplasm	1.61e-05	6.3e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.6e-05	6.24e-05	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—peripheral nervous system neoplasm	1.59e-05	6.19e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.58e-05	6.18e-05	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—peripheral nervous system neoplasm	1.57e-05	6.15e-05	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.49e-05	5.83e-05	CcSEcCtD
